Shares of Ultragenyx Pharmaceutical, a biotech firm based in Novato, California, dropped sharply on Thursday morning, falling over 40% in pre‑market trading. The decline follows the company’s announcement that its late‑stage trial of apazunersen, a treatment aimed at Angelman syndrome, failed to meet its primary endpoint of improving cognitive skills and also missed secondary measures of overall patient response.
Trial results and immediate impact
The randomized, placebo‑controlled study enrolled participants with Angelman syndrome, a rare neurodevelopmental disorder that impairs typical brain development in childhood. According to Ultragenyx, there were no statistically significant differences between the drug‑treated group and the placebo group on any of the measured outcomes. The company said it will review the program’s future direction in light of the data.
Analyst reactions
Market analysts were quick to weigh in. Jefferies analyst Maury Raycroft described the outcome as “unambiguously negative” and warned it could further erode investor confidence. TD Cowen noted that the failure removes a key growth driver for the company, while Cantor Fitzgerald’s Kristen Kluska cautioned that Ultragenyx may need to cut spending substantially before investors consider rebuilding a position.
Company response
Ultragenyx said it will implement “significant expense reductions” to manage its high operating costs. The company’s leadership emphasized that the decision reflects a disciplined approach to preserving cash while it reassesses its pipeline priorities.
Broader industry implications
The setback also raises questions for competitors developing similar therapies. Jefferies highlighted that the failure could increase risk for rivals such as Ionis Pharmaceuticals and Oak Hill Bio, which are pursuing comparable treatments for Angelman syndrome.
Financial snapshot
Before the news broke, Ultragenyx’s stock was up 15.4% year‑to‑date, with a market valuation of roughly $2.62 billion, according to LSEG data. Following the trial results, at least five brokerage firms lowered their price targets for the stock.
What this means for patients and families
Angelman syndrome currently has no approved disease‑modifying therapies. The trial’s failure is a disappointment for the patient community, which has been hoping for a treatment that could improve cognitive function and overall quality of life. While the setback is significant, Ultragenyx’s statement that it will continue to evaluate its pipeline suggests that research into new options may still be underway.
Looking ahead
Investors and observers will watch closely how Ultragenyx reallocates resources and whether it can bring other pipeline candidates to market. The company’s next steps will likely focus on cost control, strategic prioritization of its remaining programs, and communication with stakeholders about its long‑term vision.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
